Health Care Services

Jin Xin Reproductive Spends on Stock Repurchase

Jin Xin Reproductive Announces 2025 Earnings Report and Shareholder Return Plans

JXR released FY2025 Q3 earnings on March 26 (BJT), actual revenue HKD 743.62 M, actual EPS HKD 0.0111

JXR released FY2025 9 Months Earnings on March 26 (BJT), actual revenue HKD 2.139 B, actual EPS HKD -0.411

JXR released FY2025 Annual Earnings on March 26 After-Market (BJT), Actual Revenue: HKD 2.895 B (Forecast: HKD 2.994 B), Actual EPS: HKD -0.3934 (Forecast: HKD -0.3725)

JXR released FY2025 Q4 earnings on March 26 After-Market (BJT), actual revenue HKD 756.45 M, actual EPS HKD 0.0113

JXR to Release FY2025 Earnings on March 26 After-Market (BJT), Forecast Revenue HKD 3.052 B, EPS HKD -0.3797

Huachang Securities Issues Report Forecasting Jin Xin Reproductive's 2025-2027 Performance

HRC Investment Reduces Holdings in JSR International by 8.63 million shares

Jin Xin Reproductive Reports Mid-Year Loss, Fertility Industry Faces Challenges

CICC Downgrades JSR Fertility's Profit Forecast but Maintains 'Outperform Industry' Rating

Jin Xin Reproductive Reports Q1 2025 Revenue Drop; JPMorgan Cuts Rating

Dong Yang Increases Holdings in JSR Holdings

Jin Xin Reproductive Releases Half-Year Report: Revenue Decreases, Shareholder Loss Widens

JXR released FY2025 Q1 earnings on August 25 (BJT), actual revenue HKD 690.02 M, actual EPS HKD -0.2088

JXR released FY2025 Semi-Annual Earnings on August 25 After-Market (BJT), actual revenue HKD 1.395 B (forecast HKD 1.478 B), actual EPS HKD -0.4222 (forecast HKD 0.0547)

JXR released FY2025 Q2 earnings on August 25 After-Market (BJT), actual revenue HKD 705.19M, actual EPS HKD -0.2134

JXR to Release FY2025 Q2 Earnings on August 25 After-Market (BJT)

JinXin Reproductive Expected to Report Up to RMB 1.09 Billion Loss in H1 2025

Jin Xin Reproductive Adjusts Nomination Committee Members

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

01951

HRC Fertility has opened a new location in Beverly Hills, coinciding with Women's Health Month and National Infertility Awareness Week. The facility aims to enhance access to IVF and fertility treatments in the area. The grand opening event featured a ribbon-cutting ceremony attended by community leaders and physicians. The new center offers advanced technologies and personalized care, reflecting HRC Fertility's commitment to supporting individuals and couples in their family-building journey. The expansion is also supported by California's SB 729, which increases insurance coverage for fertility treatments.

prnewswire

12:50 ETHRC Fertility Celebrates Beverly Hills Grand Opening, Spotlighting Fertility Care as Women's Health Month Begins

SBIO

LABU

HRC Fertility announces Dr. Christo G. Zouves has been appointed to the San Mateo County Medical Association Board of Directors as a Director-at-Large, serving until December 31, 2027. He will also serve as an Alternate Delegate. Dr. Zouves, a leading reproductive endocrinologist, aims to support the SMCMA's mission to advocate for physicians and improve healthcare outcomes. With over 30 years of experience, he has contributed significantly to reproductive medicine and founded the Zouves Foundation for Reproductive Medicine. The SMCMA represents over 1,600 physicians in the county.

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares US Healthcare Providers

Proshares UltraShort Nasdaq Biotech

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

VG Health

SPDR S&P Health

VanEck Biotech ETF

Health Care Select Sector SPDR

12:13 ETHRC Fertility's Dr. Christo G. Zouves Appointed to San Mateo County Medical Association Board of Directors

Jinxin Fertility Group Ltd. reported a 7.5% year-on-year increase in new patient visits for infertility and a 5.2% rise in oocyte pick-up cycles for the four months ending April 30, 2026. Growth was strongest in the Greater Bay Area and overseas markets, driven by new capacity and clinic upgrades. Despite slight declines in Chengdu due to regulatory changes, third-generation IVF cycles surged 16.8%. The company maintains a Buy rating with a price target of HK$3.80, reflecting its strong competitive position in the fertility services market.

Tip Ranks

Jinxin Fertility Posts Solid Early-2026 Growth on China and Overseas IVF Demand

HRC Fertility has received multiple honors at the 2026 Hermes Creative Awards, including a Platinum award for its campaign addressing the stigmatizing term "geriatric pregnancy." The organization also earned a Gold award for its Needle-Free IVF innovation and two Honorable Mentions for its brand video and Gift Voucher Program. These accolades reflect HRC Fertility's commitment to patient-centered care and clinical innovation. The awards come as the organization continues to expand its services, recently being named to Newsweek’s Best Fertility Clinics 2026 list.

MorningStar

HRC Fertility Earns Platinum, Gold and Multiple Honors at 2026 Hermes Creative Awards

159849

516610

159883

Jinxin Fertility Group Ltd. has cancelled 52.7 million repurchased shares, reducing its total issued share capital to 2.7 billion shares. This move aims to enhance net asset value and earnings per share, reflecting the company's commitment to shareholder value. The company plans to continue this strategy for future buybacks. Currently, the stock holds a Hold rating with a price target of HK$2.50. Jinxin operates in the fertility and assisted reproductive services sector, focusing on the growing reproductive healthcare market in Asia.

INVO Fertility

China Merchants CSI Biotechnology Theme ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

iShares US Medical Devices

China Merchants CSI All Share Medical Apparatus and Instruments ETF

E Fund CSI Biotechnology Theme ETF

SPDR S&P Health Equip

ChinaAMC CSI All Share Health Care Devices ETF

ChinaAMC CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Jinxin Fertility Cancels 52.7 Million Repurchased Shares to Lift Per-Share Metrics

Guotai Haitong analyst maintained a Buy rating on Jinxin Fertility Group Ltd. on March 29 and set a price target of HK$2.70.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Jinxin Fertility Group Ltd. is a Strong Buy with an average price target of HK$3.33.

Guotai Haitong Remains a Buy on Jinxin Fertility Group Ltd. (1951)

Jinxin Fertility Group (SEHK:1951) reported a first half FY 2025 revenue of C¥1.29b and a basic EPS loss of C¥0.39, indicating profitability concerns. The company experienced a significant decline in revenue and a net loss of C¥976m over the trailing 12 months. Despite trading at a premium P/S of 2.1x, critics question the valuation given the ongoing losses. While bullish investors see potential upside based on projected revenue growth and a DCF fair value of HK$6.92, skeptics urge caution due to the current financial performance.

Simplywall

Jinxin Fertility Group FY 2025 Loss Spurs Debate On Premium Valuation Narratives

JXR announced its full-year results for the year ended last December, with a revenue of RMB 2.649 billion, a year-on-year decrease of 5.8%. It turned from profit to a loss of RMB 976 million, compared to a profit of RMB 283 million in the same period last year; the loss per share was RMB 0.36. A final dividend of HKD 0.0418 was declared, while no dividend was declared in the same period last year

AASTOCKS

"Performance" JXR turned from profit to loss last year, losing 976 million RMB, and declared a final dividend of 4.18 HK cents

JXR(01951.HK)